0000914190-21-000037.txt : 20210209
0000914190-21-000037.hdr.sgml : 20210209
20210209172413
ACCESSION NUMBER: 0000914190-21-000037
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210205
FILED AS OF DATE: 20210209
DATE AS OF CHANGE: 20210209
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Eansor Norman David
CENTRAL INDEX KEY: 0001270905
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-17272
FILM NUMBER: 21607952
MAIL ADDRESS:
STREET 1: 8100 SOUTHPARK WAY, A-8
CITY: LITTLETON
STATE: CO
ZIP: 80120
FORMER NAME:
FORMER CONFORMED NAME: EANSOR N DAVID
DATE OF NAME CHANGE: 20031120
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: BIO-TECHNE Corp
CENTRAL INDEX KEY: 0000842023
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 411427402
STATE OF INCORPORATION: MN
FISCAL YEAR END: 0630
BUSINESS ADDRESS:
STREET 1: 614 MCKINLEY PL N E
CITY: MINNEAPOLIS
STATE: MN
ZIP: 55413
BUSINESS PHONE: 6123798854
MAIL ADDRESS:
STREET 1: 614 MCKINLEY PLACE NE
CITY: MINNEAPOLIS
STATE: MN
ZIP: 55413
FORMER COMPANY:
FORMER CONFORMED NAME: TECHNE CORP /MN/
DATE OF NAME CHANGE: 19920703
4
1
edgar.xml
PRIMARY DOCUMENT
X0306
4
2021-02-05
0000842023
BIO-TECHNE Corp
TECH
0001270905
Eansor Norman David
8100 SOUTHPARK WAY, A-8
LITTLETON
CO
80120
0
1
0
0
President-Protein Sciences
Common Stock
2021-02-05
4
M
0
14114
106.59
A
15432
D
Common Stock
2021-02-05
4
M
0
18819
106.59
A
34251
D
Common Stock
2021-02-05
4
S
0
6000
378.2871
D
28251
D
Common Stock
2021-02-05
4
S
0
4500
379.6249
D
23751
D
Common Stock
2021-02-05
4
S
0
12833
380.497
D
10918
D
Common Stock
2021-02-05
4
S
0
2900
381.5155
D
8018
D
Common Stock
2021-02-05
4
S
0
3700
382.6043
D
4318
D
Common Stock
2021-02-05
4
S
0
1900
384.1518
D
2418
D
Common Stock
2021-02-05
4
S
0
1100
385.5918
D
1318
D
Stock Options (Right to Buy)
106.59
2021-02-05
4
M
0
14114
0
D
2023-08-18
Common Stock
14114
0
D
Stock Options (Right to Buy)
106.59
2021-02-05
4
M
0
18819
0
D
2023-08-18
Common Stock
18819
0
D
Stock Options (Right to Buy)
125.05
2024-08-09
Common Stock
11982
11982
D
Stock Options (Right to Buy)
125.05
2024-08-09
Common Stock
15976
15976
D
Restricted Stock Units
Common Stock
2537
2537
D
Stock Options (Right to Buy)
177.32
2025-08-08
Common Stock
13550
13550
D
Stock Options (Right to Buy)
177.32
2025-08-08
Common Stock
18066
18066
D
Restricted Stock Units
Common Stock
3151
3151
D
Stock Options (Right to Buy)
190.41
2026-08-07
Common Stock
15948
15948
D
Stock Options (Right to Buy)
190.41
2026-08-07
Common Stock
21265
21265
D
Restricted Stock Units
Common Stock
2575
2575
D
Stock Options (Right to Buy)
267.87
2027-08-05
Common Stock
11488
11488
D
Stock Options (Right to Buy)
267.87
2027-08-05
Common Stock
15318
15318
D
Stock Options (Right to Buy)
267.87
2027-08-05
Common Stock
24975
24975
D
Stock Options (Right to Buy)
267.87
2027-08-05
Common Stock
24975.0
24975.0
D
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $378.00 to $378.94, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $379.03 to $380.01, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $380.065 to $381.055, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $381.095 to $382.01, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $382.26 to $383.07, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $383.93 to $384.39, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $385.415 to $385.77, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
Fully exercisable.
Options to purchase 3,994 shares vest on each of 8/9/2018, 8/9/2019, 8/9/2020 and 8/9/2021.
Vests in full or in part on 8/8/2021 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
Options to purchase 4,517 shares vest on each of 8/8/2019 and 8/8/2020 and options to purchase 4,516 shares vest on each of 8/8/2021 and 8/8/2022.
Vests in full or in part on 8/7/2022 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
Options to purchase 5,317 shares vest on 8/7/2020 and options to purchase 5,316 shares vest on each of 8/7/2021, 8/7/2022 and 8/7/2023.
Vests in full or in part on 8/5/2023 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
Options to purchase 3,830 shares vest on each of 8/5/2021 and 8/5/2022 and options to purchase 3,829 shares vest on each of 8/5/2023 and 8/5/2024.
Vests in full on the date performance of certain product revenue goals during the period of fiscal 2021-2023 is certified by the Administrator, in no event earlier than 8/5/2021
Options to purchase 8,325 shares vest on each of 8/5/2021, 8/5/2022 and 8/5/2023.
/s/ Brenda S. Furlow as Attorney-in-Fact for N. David Eansor pursuant to Power of Attorney previously filed.
2021-02-09